Editorial Commentary: Striking a balance: Individualizing antithrombotic therapy after myocardial infarction

Trends in Cardiovascular Medicine

Volumn 26, Issue 4, 2016, Pages 335-336

  Zlotnick, David M ^a   Canty, John M ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b University at Buffalo SUNY   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; RIVAROXABAN; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ARTERIAL THROMBOEMBOLISM; BLEEDING; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MEDICAL DECISION MAKING; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SCORING SYSTEM; SECONDARY PREVENTION; THROMBOCYTE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; COMBINATION DRUG THERAPY; MYOCARDIAL INFARCTION;

ANTICOAGULANTS; ASPIRIN; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 84949982590     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.09.003     Document Type: Editorial

References (10)

1. Park Y., Franchi F., Rollini F., Angiolillo DJ. Update on oral antithrombotic therapy for secondary prevention of ischemic events follow non-ST segment elevation myocardial infarction. Trends Cardiovasc Med 2015, (in press). http://dx.doi.org/10.1016/j.tcm.2015.08.002.
2. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey Study on Atrial Fibrillation. Chest 2010, 137:263-272.
3. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
4. Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
5. Fox K.A., Dabbous O.H., Goldberg R.J., Pieper K.S., Eagle K.A., Van de Werf F., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Br Med J 2006, 333:1091.
6. Thukkani A.K., Agrawal K., Prince L., Smoot K.J., Dufour A.B., Cho K., et al. Long-term outcomes in patients with diabetes mellitus related to prolonging clopidogrel more than 12 months after coronary stenting. J Am Coll Cardiol 2015, 66:1091-1101.
7. Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G., et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Eng J Med 2014, 371:2155-2166.
8. Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Eng J Med 2012, 366:9-19.
9. Subherwal S., Bach R.G., Chen A.Y., Gage B.F., Rao S.V., Newby L.K., et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the Crusade (Can Rapid risk stratification of Unstable angina Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 2009, 119:1873-1882.
10. Genereux P., Giustino G., Witzenbichler B., Weisz G., Stuckey T.D., Rinaldi M.J., et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 2015, 66:1036-1045.